Program
lasofoxifene
Also written as “Lasofoxifene”, “Lasofoxifene in combination with abemaciclib” and “Lasofoxifene and abemaciclib (VERZENIO (R)).”.
Its studies are mostly in Osteoporosis · Breast Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ligand Pharmaceuticals | 40 open or running | phase 3since Aug 30, 2005 | Aug 30, 2005 | none ahead |
| Sermonix Pharmaceuticals | 20 open or running | phase 2since Dec 14, 2018 | Dec 14, 2018 | none ahead |
| LeonaBio | 11 open or running | phase 3since Jan 13, 2023 | Jan 13, 2023 | Apr 2027phase 3 · NCT05696626 |
- Named in fosun pharma’s own pipeline as
HLX78 (lasofoxifene)
, phase 3, as of Sep 21, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 30, 2005First study: phase 3 study in OsteoporosisNew to Ligand PharmaceuticalsLigand Pharmaceuticals · NCT00141323 · 8,556 enrolled · United States, Argentina, Australia and more
- Aug 31, 2005Phase 2 study in OsteoporosisLigand Pharmaceuticals · NCT00143273 · 497 enrolled · Japan, Korea, Republic of, Taiwan
- Sep 9, 2005Phase 3 study in OsteoporosisLigand Pharmaceuticals · NCT00163137 · 540 enrolled · United States
- Apr 30, 2008Phase 2 study in Bone Diseases, MetabolicLigand Pharmaceuticals · NCT00674453 · 51 enrolled · United Kingdom
- Dec 14, 2018Sermonix Pharmaceuticals's first study: phase 2 study in Breast NeoplasmsNew to Sermonix PharmaceuticalsSermonix Pharmaceuticals · NCT03781063 · 100 enrolled · United States, Canada, Israel
- Jun 4, 2020Phase 2 study in Breast NeoplasmsSermonix Pharmaceuticals · NCT04432454 · 29 enrolled · United States
- Jan 13, 2023LeonaBio's first study: phase 3 study in Breast NeoplasmsNew to LeonaBioLeonaBio · NCT05696626 · 600 planned · United States, Australia, Belgium and more
Ahead
- Apr 2027Primary completion: phase 3 study in Breast NeoplasmsLeonaBio · NCT05696626
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05696626Breast Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | LeonaBio | Apr 2027 | 600 |
| NCT04432454Breast Neoplasms · United States | 2 | Completed | Sermonix Pharmaceuticals | Jan 28, 2025 | 29 |
| NCT03781063Breast Neoplasms · United States, Canada, Israel | 2 | Completed | Sermonix Pharmaceuticals | May 8, 2025 | 100 |
| NCT00674453Bone Diseases, Metabolic · United Kingdom | 2 | Completed | Ligand Pharmaceuticals | 51 | |
| NCT00163137Osteoporosis · United States | 3 | Completed | Ligand Pharmaceuticals | Oct 2005 | 540 |
| NCT00143273Osteoporosis · Japan, Korea, Republic of, Taiwan | 2 | Completed | Ligand Pharmaceuticals | Mar 2006 | 497 |
| NCT00141323Osteoporosis · United States, Argentina, Australia and more | 3 | Completed | Ligand Pharmaceuticals | Dec 2007 | 8,556 |
How it is read
Names in the registry
- “Lasofoxifene”, 4 entries
- “lasofoxifene”, 4 entries
- “Lasofoxifene in combination with abemaciclib”, 1 entry
- “Lasofoxifene and abemaciclib (VERZENIO (R)).”, 1 entry
Conditions, from the studies’ own filings
- Osteoporosis, 4 studies
- Breast Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.